XELOX方案联合参麦注射液治疗老年晚期胃癌的疗效分析

目的探讨XELOX(奥沙利铂+卡培他滨)方案联合参麦注射液治疗老年晚期胃癌的临床疗效。方法将65例老年晚期胃癌患者随机分成治疗组和对照组,治疗组33例,给予XELOX方案联合参麦注射液治疗,对照组32例,仅给予XELOX方案化疗,观察两组免疫功能变化、近期疗效及毒副反应。结果治疗组的CR、PR和RR分别为6.1%、51.5%和57.6%,均高于对照组,但P>0.05。治疗组治疗结束后CD3+、CD4+、CD16+CD56+的比例和CD4+/CD8+比值显著上升,CD8+效应细胞比例下降,治疗前后有明显差异(P<0.05)。而对照组治疗前后无明显变化(P>0.05)。治疗组骨髓抑制、胃肠道反应及手足综合症的发生率均低于对照组,有显著差异(P<0.05)。结论参麦注射液联合XELOX方案治疗晚期胃癌能提高疗效,改善机体免疫功能,减轻毒副反应。

Effect analysis of combination of Shenmai injection and XELOX chemotherapy in treatment of elderly patients with advanced gastric cancer

Objective To evaluate the clinical efficacy of Shenmai injection and XELOX chemotherapy in treatment of elderly patients with advanced gastric cancer.Methods Totally 65 cases of elderly patients with advanced gastric cancer were randomly divided into treatment group and control group.In the treatment group,33 patients received XELOX regimen chemotherapy combined with Shenmai injection treanment.32 patients in the control group only received XELOX regimen chemotherapy.The changes of immune function,the recent efficacy and toxicity were observed.Results The CR,PR and RR in the treatment group were 6.1%,51.5% and 57.6%,were higher than those of the control group respectively,but there were no significant difference(P>0.05).In the treatment group,the percentages of CD3+,CD4+,CD16+CD56+ effect cells and the proportion of CD4+/CD8+ increased and the CD8+ effect cells decreased significantly(P<0.05).The control group showed no significant change(P>0.05).The incidence rate of bone marrow suppression,gastrointestinal tract and hand-foot syndrome in the treatment group were significantly lower than those of the control group(P<0.05).Conclusions The regimen of Shenmai injection in combination wiith XELOX programs in treatment of advanced gastric cancer can improve the efficacy of the treatment,improve immune function and reduce toxicity.